A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector

Blood

Volumn 97, Issue 8, 2001, Pages 2406-2412

  Zhao, Robert C ^a   Jiang, Yuehua ^a   Verfaillie, Catherine M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CYTOKINE; FIBRONECTIN; ONCOPROTEIN; VIRUS VECTOR;

APOPTOSIS; ARTICLE; CELL MIGRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; MOLECULAR MODEL; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; SIGNAL TRANSDUCTION;

EID: 0035871781     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2406     Document Type: Article

References (51)

1. The Philadelphia chromosome translocation: A paradigm for understanding leukemia
2. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
3. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro
4. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
5. The P190, P210, and P230 forms of the BCP/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
6. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
7. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
8. BCR/ABL induces multiple abnormalities of cytoskeletal function
9. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells
10. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
11. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway
12. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl
13. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia
14. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival
15. Evaluation of "discordant maturation" in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (GM-CFU)
16. New understanding of the pathogenesis of CML: A prototype of early neoplasia
17. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia
18. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV
19. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia
20. + cells
21. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
22. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line
23. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation
24. Notch1 expression in early lymphopoiesis influences B versus T lineage determination
25. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses
26. Improved retroviral transduction of hematopoietic progenitors by combining methods to enhance virus-cell interaction
27. Activation-dependent α5β1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells
28. + cells
29. Gene therapy for chronic myelogenous leukemia (CML): A retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo
30. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function
31. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation
32. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
33. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
34. BCR-ABL accelerates C2-ceramide-induced apoptosis
35. Abnormal kinetics of colony formation by erythroid burst-forming units (BFU-E) in chronic myeloid leukaemia
36. The BCP/ABL oncogene alters the chemotactic response to stromal-derived factor-1α
37. +/HLA-DR - Phenotype in early chronic phase but not advanced phase CML
38. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression
39. Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: Implications for anatomical localization and developmental stage specific regulation of hematopoiesis
40. Multi-lineage expansion potential of primitive hematopoietic progenitors: Superiority of umbilical cord blood compared to mobilized peripheral blood
41. Ontogeny-associated changes in the cytokine responses of primitive human haemopoietic cells
42. + cells
43. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase
44. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: An in vivo model of chronic myelogenous leukemia biology
45. Chromosome abnormalities in malignant diseases
46. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors
47. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide
48. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia
49. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
50. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
51. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity, restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors